Denali Therapeutics received FDA accelerated approval for Avlayah, the first new treatment for Hunter syndrome in nearly 2 decades. The approval validates the company's TransportVehicle platform but comes as 2 major pipeline programs face clinical and partnership setbacks.
Denali Therapeutics Inc. received US approval for Avlayah, its enzyme replacement therapy for Hunter syndrome, marking the first new treatment option for the rare pediatric disorder in nearly 2 decades.
"Avlayah addresses a critical unmet need for children with neurological symptoms of Hunter syndrome," said Sam Goldstein, PhD, healthcare analyst at Edgen. "The approval validates Denali's TransportVehicle platform, which enables drug delivery across the blood-brain barrier."
The accelerated approval covers pediatric patients with mucopolysaccharidosis type II, or Hunter syndrome, a lysosomal storage disorder affecting roughly 1 in 100,000 live births. Avlayah is designed to target neurological symptoms when initiated early in the disease course, addressing a limitation of prior therapies that could not cross the blood-brain barrier. The FDA granted the approval under its accelerated pathway based on biomarker data.
The approval provides a near-term commercial catalyst for Denali, which had no marketed products prior to Avlayah. However, the company faces significant headwinds across its pipeline. In May 2026, Denali and partner Biogen Inc. reported disappointing mid-stage results for BIIB122 (DNL151) in early-stage Parkinson's disease, with the study missing both primary and secondary endpoints. The partners subsequently discontinued development of BIIB122 in idiopathic Parkinson's disease.
Denali will continue to independently advance the Phase IIa BEACON study evaluating BIIB122 in patients carrying pathogenic LRRK2 variants, with data expected in the first half of 2027. The study is funded through a collaboration and development agreement with a third party.
In April 2026, partner Takeda Pharmaceutical Co. ended its collaboration on DNL593 for frontotemporal dementia associated with GRN mutations, returning full rights to Denali. Takeda said the decision reflected strategic priorities rather than safety or efficacy concerns, though the exit shifts the full development and financial burden to Denali.
Denali's remaining pipeline includes DNL126 for Sanfilippo syndrome type A, DNL952 for Pompe disease, and DNL628 for Alzheimer's disease, alongside early-stage candidates including DNL921 for Alzheimer's, DNL111 for Parkinson's and Gaucher diseases, DNL622 for Hurler syndrome, and DNL422 for Parkinson's disease. The company also maintains collaborations with Sanofi and Biogen on other programs.
The Avlayah approval gives Denali its first commercial revenue stream, but the lost pipeline value from the BIIB122 discontinuation and Takeda exit introduces uncertainty about the company's longer-term growth trajectory. Investors will watch for initial Avlayah sales figures and the BEACON study readout in the first half of 2027.
This article is for informational purposes only and does not constitute investment advice.
